Enovix Corp
For the period ended Mar 30, 2025. Filed May 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 30, 2025 · Filed May 2, 2025
ENVX$2.64-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and par value amounts)
| March 30,2025 | December 29, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $189,874 | $272,869 |
| Short-term investments | 58,281 | — |
| Accounts receivable, net | 2,897 | 4,566 |
| Notes receivable, net | 1,255 | 4 |
| Inventory | 10,483 | 7,664 |
| Prepaid expenses and other current assets | 7,382 | 9,903 |
| Total current assets | 270,172 | 295,006 |
| Property and equipment, net | 165,775 | 167,947 |
| Customer relationship intangibles and other intangibles, net | 35,205 | 36,394 |
| Operating lease, right-of-use assets | 12,921 | 13,479 |
| Goodwill | 12,217 | 12,217 |
| Other assets, non-current | 2,755 | 2,126 |
| Total assets | $499,045 | $527,169 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $20,610 | $9,492 |
| Accrued expenses | 8,540 | 19,843 |
| Accrued compensation | 6,481 | 8,228 |
| Short-term debt | 10,367 | 9,452 |
| Deferred revenue | 6,630 | 3,650 |
| Other liabilities | 5,161 | 3,036 |
| Total current liabilities | 57,789 | 53,701 |
| Long-term debt, net | 169,185 | 169,820 |
| Warrant liability | 12,584 | 28,380 |
| Operating lease liabilities, non-current | 12,638 | 13,293 |
| Deferred revenue, non-current | 300 | 3,774 |
| Deferred tax liability | 8,751 | 8,784 |
| Other liabilities, non-current | 14 | 14 |
| Total liabilities | 261,261 | 277,766 |
| Commitments and Contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; authorized shares of 1,000,000,000; issued and outstanding shares of 191,715,117 and 190,559,335 as of March 30, 2025 and December 29, 2024, respectively | 19 | 19 |
| Additional paid-in-capital | 1,079,904 | 1,067,951 |
| Accumulated other comprehensive loss | (184) | (143) |
| Accumulated deficit | (844,596) | (821,086) |
| Total Enovix stockholders’ equity | 235,143 | 246,741 |
| Non-controlling interest | 2,641 | 2,662 |
| Total equity | 237,784 | 249,403 |
| Total liabilities and equity | $499,045 | $527,169 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.